Coronary Artery Disease Clinical Trial
Official title:
The Association of Iodixanol (Visipaque) to Renal Function and Cardiac and Cerebrovascular Events in STEMI Patients Undergoing Primary PCI: A Prospective, Multi-National, Multi-Center, Open-Label, Observational Study
Verified date | January 2022 |
Source | GE Healthcare |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to prospectively observe the incidence rate of acute kidney injury (AKI), major adverse renal and cardiovascular events (MARCE) in participants who were diagnosed with ST-segment elevation myocardial infarction (STEMI) and have completed primary percutaneous coronary intervention (PCI) procedure following an injection of iso-osmolar contrast medium iodixanol (Visipaque) during the in-hospital period and up to 30 days post-PCI follow-up period. The study will provide a better safety profile of Visipaque as the contrast medium in PCI procedure.
Status | Completed |
Enrollment | 2755 |
Est. completion date | June 7, 2021 |
Est. primary completion date | June 7, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Participants may be included in the study if they meet all of the following criteria: - The participant is over 18 years' old - The participant with ST segment elevation myocardial infarction (STEMI) diagnosis has completed primary percutaneous coronary intervention (PCI) procedure and Visipaque was used as the contrast medium in the procedure - The participant completed pre-procedural serum creatinine (SCr) test at the same hospital where PCI procedure was conducted, and the SCr test should be conducted with the same methodology before and after the procedure - The participant has signed and dated the written informed consent form Exclusion Criteria: Participants must be excluded from participating in this study if they meet any of the following criteria: - The participant has any contraindications to Visipaque (e.g., manifest thyrotoxicosis, history of serious hypersensitivity reaction to iodinated contrast media) - The participant is pregnant or lactating - The participant has been previously enrolled in this study - The participant is currently under renal dialysis - The participant presents with a terminal (life expectation <1 month), serious, or life-threatening disease, or any medical or psychiatric condition, or any condition where study participation may compromise the management of the participant - The participant has other reasons that in the judgement of the investigator is unsuitable for participation in the study |
Country | Name | City | State |
---|---|---|---|
China | Ankang City Central Hospital | Ankang | Shaanxi |
China | Peking University First Hospital | Beijing | |
China | Wangjing Hospital of CACMS | Beijing | |
China | China-Japan Friendship Hospital of Jilin University | Changchun | Jilin |
China | The Second Hospital of Jilin University | Changchun | Jilin |
China | The Third Xiangya Hospital of Central South University | Changsha | Hunan |
China | Sichuan Provincial People's Hospital | Chengdu | Sichuan |
China | The Second Affiliated Hospital of Chongqing Medical University | Chongqing | Gansu |
China | Shanxi Province Fenyang Hospital | Fengyang | Shanxi |
China | Dongguan Kanghua Hospital | Guangdong | Guangdong |
China | The First Affiliated Hospital of Jinan University | Guangzhou | Guangdong |
China | The First Affiliated Hospital, Sun Yat-sen University | Guangzhou | Guangdong |
China | Kaifeng Central Hospital | Kaifeng | Contact: |
China | Lanzhou University Second Hospital | Lanzhou | Gansu |
China | The First Hospital of Lanzhou University | Lanzhou | Gansu |
China | Linzi District People's Hospital | Linzi | Shandong |
China | Nanjing Jiangning Hospital | Nanjing | Jiangsu |
China | People's Hospital of Jiangsu Province | Nanjing | Jiangsu |
China | Ningbo First People's Hospital | Ningbo | Zhejiang |
China | Shanghai Tongren Hospital | Shanghai | |
China | Shanghai Zhongshan Hospital | Shanghai | |
China | Shaoxing Hospital of Zhejiang University | Shaoxing | Zhejiang |
China | The People's Hospital of Liaoning Province | Shenyang | Liaoning |
China | Hebei General Hospital | Shijiazhuang | Hebei |
China | Shijiazhuang First Hospital | Shijiazhuang | Hebei |
China | Shijiazhuang First Hospital Central Hospital Campus | Shijiazhuang | Hebei |
China | The Second Hospital of Hebei Medical University | Shijiazhuang | Hebei |
China | Shanxi Cardiovascular Hospital | Taiyuan | Shanxi |
China | Taiyuan Central Hospital | Taiyuan | Shanxi |
China | Tianjin Chest Hospital | Tianjin | |
China | Wuhan Asia Heart Hospital | Wuhan | Hubei |
China | Wuhan Central Hospital | Wuhan | Hubei |
China | Xi'an No.3 Hospital | Xi'an | Shanxi |
China | Affiliated Hospital of Guangdong Medical University | Zhanjiang | Guangdong |
China | The First Affiliated Hospital of Henan University of CM | Zhengzhou | Henan |
Korea, Republic of | Seoul National University Bundang Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
GE Healthcare |
China, Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of the Incidence Rate of AKI in STEMI Participants Undergoing Primary PCI Using Visipaque | AKI which is defined as a serum creatinine (SCr) increase of = 0.3 mg/dL (= 26.4 umol/L) or increase to =150% (=1.5-fold) from baseline values within 48-72 hours. | Within 48-72 hours post PCI | |
Secondary | Assessment of the Incidence Rate of MARCE in STEMI Participants Undergoing Primary PCI Using Visipaque Within 72 Hours Post-PCI | MARCE includes cardiac death, re-infarction, target lesion revascularization (TLR), stent thrombosis, unstable angina, stroke, transient ischemic attack (TIA), AKI, renal failure requiring dialysis. | Within 72 hours post-PCI | |
Secondary | Assessment of the Incidence Rate of Each Event of MARCE (except AKI) in STEMI Participants Undergoing Primary PCI Using Visipaque Within 72 Hours Post-PCI | MARCE includes cardiac death, re-infarction, TLR, stent thrombosis, unstable angina, stroke, TIA, AKI, renal failure requiring dialysis. | Within 72 Hours post-PCI | |
Secondary | Assessment of the Incidence Rate of MARCE (Except AKI) in STEMI Participants Undergoing Primary PCI Using Visipaque From 72 hours to 30 days Post-PCI | MARCE includes cardiac death, re-infarction,TLR, stent thrombosis, unstable angina, stroke, TIA, AKI, renal failure requiring dialysis. | From 72 hours to 30 days post-PCI | |
Secondary | Assessment of the Incidence Rate of Each Event of MARCE (except AKI) in STEMI Participants Undergoing Primary PCI Using Visipaque From 72 hours to 30 Days Post-PCI | MARCE includes cardiac death, re-infarction, TLR, stent thrombosis, unstable angina, stroke, TIA, AKI, renal failure requiring dialysis. | From 72 hours to 30 Days post-PCI | |
Secondary | All-Cause Mortality of STEMI Participants Within 30 days after primary PCI | From Baseline up to 30 days post-PCI |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |